List of Excipients in Branded Drug NUPRO CHLORHEXIDINE GLUCONATE

« Back to Dashboard

Generic Drugs Containing NUPRO CHLORHEXIDINE GLUCONATE

Company	Ingredient	NDC	Excipient
Xttrium Laboratories Inc	chlorhexidine gluconate	0116-0800	ALCOHOL
Xttrium Laboratories Inc	chlorhexidine gluconate	0116-0800	FD&C BLUE NO. 1
Xttrium Laboratories Inc	chlorhexidine gluconate	0116-0800	GLYCERIN
Xttrium Laboratories Inc	chlorhexidine gluconate	0116-0800	PEG-40 SORBITAN DIISOSTEARATE
Xttrium Laboratories Inc	chlorhexidine gluconate	0116-0800	SACCHARIN SODIUM
Xttrium Laboratories Inc	chlorhexidine gluconate	0116-0800	WATER

What are the Most Frequently-Used Excipients in NUPRO CHLORHEXIDINE GLUCONATE?

# Of NDCs	Excipient
2	ALCOHOL
2	FD&C BLUE NO. 1
2	GLYCERIN
2	PEG-40 SORBITAN DIISOSTEARATE
2	SACCHARIN SODIUM
2	WATER

NUPRO Chlorhexidine Gluconate: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: September 24, 2026

NUPRO Chlorhexidine Gluconate is a prescription dental oral rinse containing 0.12% chlorhexidine gluconate. Its commercial value is driven by dental-office distribution, periodontal maintenance, post-procedural care, and private-label opportunities rather than by a strong active-ingredient patent barrier. The main formulation priorities are chlorhexidine stability, taste management, staining control, alcohol positioning, packaging compatibility, and differentiation in dental professional channels.

What is NUPRO Chlorhexidine Gluconate?

NUPRO Chlorhexidine Gluconate is an oral rinse marketed for dental use. The product contains chlorhexidine gluconate oral-rinse equivalent to 0.12% chlorhexidine and is used as part of a professional dental treatment regimen for reduction of gingivitis-associated plaque and gingival inflammation.[1]

Attribute	NUPRO Chlorhexidine Gluconate
Active ingredient	Chlorhexidine gluconate
Strength	0.12% oral-rinse concentration
Dosage form	Oral solution
Primary channel	Dental professionals and prescription dispensing
Therapeutic area	Gingivitis, plaque control, periodontal care
Administration	Oral rinse; generally used twice daily under dental direction
Manufacturer/brand context	NUPRO dental product portfolio associated with Dentsply Sirona
Regulatory category	Prescription dental oral rinse
Primary competitors	PerioGard, generic chlorhexidine gluconate oral rinses, dental-office private labels
Main commercial limitation	Tooth and oral-surface staining, taste effects, altered taste perception, and limited long-term use

The reference U.S. chlorhexidine gluconate oral-rinse labeling identifies a 0.12% solution and warns of brown staining of teeth, restorations, and oral surfaces, increased calculus formation, and taste disturbance.[1] Those adverse-use characteristics define the main opportunity for excipient and packaging innovation.

What excipients are used in NUPRO Chlorhexidine Gluconate?

Public labeling identifies a conventional aqueous oral-rinse excipient system. The formulation includes water and commonly used oral-rinse excipients such as alcohol, flavoring, glycerin, sweetening agents, and colorants, although the precise excipient declaration can vary by NUPRO presentation and current product label.[1,2]

Functional role of the excipient system

Excipient category	Formulation function	Commercial relevance
Purified water	Primary vehicle	Controls solubility, viscosity, and mouthfeel
Alcohol, where present	Solvent, preservative support, flavor extraction	May improve solubilization but limits alcohol-free positioning
Glycerin or similar polyol	Humectant and mouthfeel modifier	Reduces harshness and supports sensory acceptability
Flavor system	Masks chlorhexidine bitterness and medicinal notes	Affects repeat use and dental-office acceptance
Sweetener	Improves palatability	Must be compatible with chlorhexidine and oral-care positioning
Colorants	Brand identification and product appearance	Can be removed for sensitive-user or clean-label positioning
pH-control components	Maintain chlorhexidine stability and sensory profile	Important for chemical stability and compatibility
Preservative system, if used	Microbial protection	Must not reduce chlorhexidine activity or create irritation

Chlorhexidine is cationic. Its compatibility profile is therefore important. Anionic surfactants and some anionic excipients can interact with chlorhexidine, reduce available active concentration, or alter antimicrobial performance. Formulators should screen surfactants, polymers, buffers, flavor components, and colorants for ionic incompatibility rather than relying only on standard oral-rinse practice.

What excipient strategy best supports a chlorhexidine oral rinse?

The most defensible strategy is to preserve chlorhexidine availability while improving sensory tolerability and reducing formulation-related barriers to use.

1. Use a low-interaction vehicle

The vehicle should avoid excipients that bind or neutralize cationic chlorhexidine. Candidate systems should be evaluated through:

• Assay of free and total chlorhexidine
• Antimicrobial activity testing
• pH stability
• Appearance and precipitation testing
• Accelerated and long-term stability
• Compatibility with bottle, cap, liner, and dosing cup materials

A low-complexity aqueous system can reduce development risk. Complex polymeric or surfactant-rich systems may improve mouthfeel, but they increase the probability of chlorhexidine interaction.

2. Develop an alcohol-free version

An alcohol-free chlorhexidine rinse could target patients who avoid alcohol-containing products, dental practices seeking a milder rinse, and institutions with product-standardization policies. The principal technical challenge is maintaining solubility, preservation, flavor performance, and microbiological quality without ethanol.

Potential approaches include:

• Aqueous glycerin or other polyol systems
• Compatible nonionic solubilizers
• Low-level preservative systems that do not reduce chlorhexidine activity
• Unit-dose packaging to reduce repeated container opening
• Optimized bottle and closure systems to reduce contamination risk

An alcohol-free product would require comparative sensory work. Removing ethanol can reduce burning, but it can also alter flavor release, viscosity, preservation, and the perception of medicinal taste.

3. Optimize taste masking without reducing activity

Chlorhexidine has a persistent bitter or medicinal taste and can affect taste perception after use. Flavor design should focus on reducing initial bitterness and residual aftertaste.

Potential approaches include:

• Mild mint or herbal flavor systems
• Reduced flavor intensity to limit lingering taste
• Nonionic flavor solubilization
• Controlled sweetener selection
• Cooling agents used at conservative levels
• Separate flavor screening for alcohol and alcohol-free versions

Strong flavor systems can create their own tolerability problems. The best commercial formulation is likely to use moderate masking rather than a high-intensity mint profile.

4. Reduce visible staining through use design

Excipients cannot eliminate the staining mechanism associated with chlorhexidine. Staining is linked to chlorhexidine use and interactions with dietary chromogens and oral surfaces.[1,3] A formulation program can still seek to reduce perceived staining through:

• Lower residual flavor and excipient deposition
• Reduced viscosity after expectoration
• Better rinse-and-spit behavior
• Dosing aids that improve volume accuracy
• Instructions that separate use from toothbrushing when appropriate
• Packaging and educational materials that set expectations for limited-duration use

Claims that a chlorhexidine formulation prevents staining would require strong clinical evidence and could create regulatory risk.

What formulations are protected by NUPRO or chlorhexidine patents?

The active ingredient and the basic 0.12% chlorhexidine oral-rinse concept are mature technologies. The primary U.S. commercial products do not appear to depend on a current, blocking patent covering chlorhexidine itself or a conventional aqueous 0.12% rinse.

Patent landscape

Patent category	Commercial position
Chlorhexidine compound patents	Generally expired or commercially irrelevant
Conventional 0.12% rinse composition	Mature technology; limited exclusivity potential
Specific flavor system	Potentially protectable if novel and non-obvious
Alcohol-free vehicle	Potentially protectable if it solves stability, activity, or sensory problems
Stain-reduction formulation	Potentially protectable, but clinical support is important
Unit-dose packaging	Potentially protectable through device or packaging claims
Sustained-release dental delivery	Potentially protectable but distinct from a conventional rinse
Method-of-use claims	Possible for specific dental procedures or patient populations
Manufacturing process	Potentially protectable if it improves stability or impurity control

A new product would likely require a differentiated formulation or delivery system to obtain meaningful patent value. A simple substitution of glycerin, flavor, or colorant would generally face obviousness risk unless supported by unexpected technical results.

What is the Orange Book status of NUPRO Chlorhexidine Gluconate?

NUPRO is a branded dental oral-rinse product, but the commercial market also includes generic chlorhexidine gluconate oral rinses and the long-established PerioGard product. Orange Book protection is therefore more relevant to the underlying approved products and any listed patents than to brand recognition alone.[4]

The commercial assessment is:

• The product is prescription-based.
• Generic chlorhexidine gluconate oral rinses are available in the U.S.
• No current, broadly blocking NUPRO patent estate is apparent from the mature generic market.
• Any patent listed for a particular NDA would need to be reviewed in the current FDA Orange Book and patent-listing records.
• Formulation changes may require an abbreviated new drug application, a supplemental approval, or another FDA pathway depending on the extent of the change.

NUPRO should not be treated as a protected innovator asset solely because it is sold under a branded dental name.

When does chlorhexidine oral-rinse exclusivity expire?

The practical exclusivity period for conventional chlorhexidine gluconate oral rinse has already ended. The market includes generic products, and the active ingredient is not a current source of meaningful composition-of-matter exclusivity.[4,5]

Exclusivity timeline

Period	Market event
1970s-1980s	Chlorhexidine oral-rinse products established in dental care
1980s-1990s	U.S. branded products, including PerioGard, developed commercial presence
Later period	Generic chlorhexidine gluconate oral rinses entered the market
Current market	Competition centers on price, dental distribution, sensory profile, packaging, and service
Future opportunity	New patents would need to cover a differentiated formulation, delivery system, or method of use

The absence of active-ingredient exclusivity does not eliminate commercial opportunity. It shifts value toward manufacturing reliability, channel access, professional recommendation, and product differentiation.

What patent opportunities exist for a new NUPRO-compatible formulation?

A reformulated product could pursue composition, process, packaging, or use claims.

Alcohol-free chlorhexidine formulation

A patent position could focus on a defined combination of:

• Chlorhexidine gluconate
• A specified polyol system
• A compatible flavor blend
• A defined pH range
• A preservative or antimicrobial-support system
• Demonstrated stability and antimicrobial retention

The claims would need to distinguish over known alcohol-free chlorhexidine rinses and other oral-care compositions.

Low-staining or improved-tolerability formulation

A formulation could seek protection for measurable improvements in:

• Residual chlorhexidine after rinsing
• Staining on standardized dental substrates
• Taste recovery time
• Burning or irritation scores
• Patient adherence
• Compatibility with dental restorations

The strongest patent applications would include comparative data against conventional 0.12% chlorhexidine products.

Unit-dose and institutional packaging

Unit-dose packaging could address:

• Dosing accuracy
• Contamination control
• Dental-office workflow
• Hospital or ambulatory-surgery use
• Travel and postoperative dispensing
• Waste reduction

Packaging claims are more defensible when the system solves a defined use problem and has testing data supporting shelf life and container-closure integrity.

Delivery-system patents

A higher-value technical program could explore:

• Mucoadhesive rinses
• Dental trays
• Gel-rinse hybrids
• Postoperative irrigation systems
• Periodontal pocket delivery
• Biodegradable films or inserts

These products would compete with established dental delivery products and would likely require more extensive clinical and regulatory development than a conventional rinse.

Which companies compete with NUPRO Chlorhexidine Gluconate?

The competitive set includes branded dental products, generic manufacturers, and dental distributors.

Competitor type	Examples	Competitive basis
Branded dental rinse	PerioGard and related chlorhexidine products	Dental professional recognition and distribution
Generic manufacturers	Multiple ANDA holders and authorized distributors	Price and pharmacy access
Dental distributors	Henry Schein, Patterson and regional suppliers	Office purchasing relationships
Dental private labels	Distributor- or practice-branded rinses	Margin, loyalty, and procurement control
Adjacent oral-care products	Essential-oil, cetylpyridinium chloride, fluoride, and peroxide rinses	Consumer tolerability and broader retail access

NUPRO’s most relevant competitive advantage is likely its integration with the broader NUPRO dental consumables portfolio rather than a unique pharmaceutical technology.

What commercial opportunities exist for NUPRO chlorhexidine excipients?

Dental-office private label

A manufacturer could offer a contract-development and manufacturing platform with:

• 0.12% chlorhexidine oral rinse
• Alcohol-free and alcohol-containing variants
• Custom flavor and color
• Practice-specific labeling
• Small-batch and regional production
• Unit-dose and bottle formats

Private-label dental products can support higher gross margins than undifferentiated generic bottles when bundled with other consumables.

Postoperative dental care

A targeted product could support use after:

• Periodontal surgery
• Implant placement
• Tooth extraction
• Oral surgery
• Scaling and root planing
• Treatment of acute gingival inflammation

Marketing claims must remain within the approved labeling or be supported through the appropriate FDA pathway.

Institutional and procedural care

Alcohol-free, unit-dose packaging may have commercial value in:

• Hospitals
• Ambulatory surgical centers
• Long-term care
• Dental schools
• Mobile dental clinics
• Public-health programs

The procurement case would depend on cost per dose, shelf life, contamination control, and workflow efficiency.

Geographic expansion

Outside the U.S., chlorhexidine oral rinses are regulated under varying national frameworks. Opportunities may exist in markets with:

• High dental-clinic density
• Expanding periodontal-care services
• Local manufacturing incentives
• Demand for alcohol-free products
• Strong distributor networks

Geographic expansion requires country-specific review of product classification, labeling, preservative rules, excipient restrictions, and registration requirements.

What FDA regulatory pathway applies to a new formulation?

A materially different chlorhexidine rinse may require more than a simple manufacturing change. The pathway depends on whether the proposed product can demonstrate pharmaceutical equivalence to an approved reference product.

Likely regulatory scenarios

Product change	Potential regulatory issue
Same strength, dosage form, route, and inactive ingredients	May fit an ANDA strategy if other requirements are met
Alcohol removed or substantially changed	May affect bioequivalence, stability, preservation, and labeling
New delivery system	May require a different application strategy
New concentration	Likely requires additional clinical and regulatory support
New indication	Requires evidence and labeling review
New unit-dose package	Requires container-closure, stability, and potentially extractables testing
New manufacturing site	Requires approved supplement or application update

The FDA’s approved-drug and generic-drug databases should be reviewed for the specific reference listed drug, current labeling, and active application status.[4,6]

How strong is the patent estate for NUPRO?

The patent estate is likely weak for the conventional product and potentially moderate for a genuinely differentiated reformulation.

Asset	Estimated strategic strength
0.12% chlorhexidine oral rinse	Low patent differentiation
Conventional aqueous excipients	Low
Alcohol-free reformulation	Moderate if supported by stability and sensory data
Stain-reduction technology	Moderate to high if clinically validated
Unit-dose packaging	Moderate
Novel dental delivery system	Moderate to high, with higher development cost
Dental-office private label	Commercially useful but not patent-protected
Manufacturing process	Moderate if it creates measurable quality or yield advantages

The strongest defensible moat is likely a combination of formulation know-how, validated manufacturing, professional distribution, and customer-specific packaging. Patents would support that moat but would not replace it.

What generic launch risks exist?

Generic launch risk is already reflected in the conventional chlorhexidine market. A new entrant would face:

• Low-cost generic competition
• Limited switching costs for dental offices
• Price pressure from distributor contracts
• FDA requirements for equivalence and stability
• Flavor and sensory dissatisfaction
• Staining-related complaints
• Dental-office preference for established suppliers
• Potential product liability exposure from off-label or prolonged use

A differentiated product can reduce direct price competition if it obtains credible professional acceptance. The strongest launch position would combine alcohol-free formulation, improved taste, unit-dose packaging, and a dental-distributor partnership.

What revenue exposure does NUPRO create for its manufacturer?

Public company disclosures generally do not isolate NUPRO chlorhexidine revenue from the broader dental consumables portfolio. Product-level revenue, gross margin, and market share should therefore not be inferred from corporate dental-segment reporting.[7]

Commercial exposure is more likely to be measured through:

• Dental-office reorder rates
• Distributor placement
• Formulary or preferred-product status
• Average selling price per bottle or dose
• Private-label conversion
• Share of periodontal-procedure kits
• Cross-selling with NUPRO prophylaxis and polishing products

Because the active ingredient is generic, the product’s revenue sensitivity is likely tied to channel execution and portfolio bundling rather than exclusivity expiration.

What licensing deals could support expansion?

Potential licensing or commercial partnerships include:

1. Dental-distributor licensing for regional private-label sales.
2. Contract manufacturing agreements with generic pharmaceutical companies.
3. Flavor-system licensing for improved taste masking.
4. Packaging partnerships for unit-dose and contamination-controlled delivery.
5. Co-development with periodontal-care companies.
6. Geographic licensing to local manufacturers in markets requiring domestic production.

A licensing deal would be more attractive if the partner contributes one of three assets: regulatory approvals, dental-office access, or validated formulation technology.

Key Takeaways

• NUPRO Chlorhexidine Gluconate is a 0.12% prescription dental oral rinse based on a mature active ingredient.
• The conventional formulation has limited patent differentiation and faces generic competition.
• The highest-value excipient opportunities are alcohol-free systems, taste masking, pH control, chlorhexidine compatibility, and preservation.
• Anionic excipients and incompatible surfactants present a significant technical risk because chlorhexidine is cationic.
• Staining and taste disturbance are the core product limitations and the main targets for innovation.
• Unit-dose packaging can create commercial value in dental offices, hospitals, postoperative care, and institutional settings.
• A new product would need formulation, packaging, manufacturing, distribution, or method-of-use differentiation to create a defensible position.
• The strongest commercial strategy is likely a dental-channel platform combining private label, professional distribution, and differentiated sensory performance.
• No material current exclusivity should be assumed for the conventional 0.12% chlorhexidine oral-rinse concept.

FAQs

Is NUPRO Chlorhexidine Gluconate alcohol-free?

The exact excipient profile depends on the product presentation and current labeling. Conventional chlorhexidine oral-rinse products may contain alcohol, while alcohol-free versions are also commercially feasible. The current package insert and NDC-specific label control the applicable formulation.

Can chlorhexidine gluconate be formulated with sodium lauryl sulfate?

Sodium lauryl sulfate is an anionic surfactant and should not be presumed compatible with chlorhexidine. Compatibility, free-active concentration, antimicrobial activity, and stability must be demonstrated before inclusion.

Is a chlorhexidine oral rinse eligible for an ANDA?

A product may be eligible for an ANDA if it demonstrates the required pharmaceutical equivalence, bioequivalence or other applicable requirements, quality, labeling, and manufacturing controls relative to the reference product. Material formulation or delivery changes can alter the regulatory pathway.

Can excipients prevent chlorhexidine tooth staining?

Excipients may reduce residual deposition or improve use characteristics, but a claim that a formulation prevents staining requires supporting clinical and laboratory evidence. Chlorhexidine-associated staining remains a known limitation of therapy.

What is the best commercial format for a dental-office chlorhexidine product?

A practical commercial platform would include a standard bottle for routine dispensing, an alcohol-free variant for tolerability-sensitive users, and unit-dose packaging for postoperative and institutional workflows. Custom flavor, label, and distributor options can support private-label sales.

References

1. DailyMed. (n.d.). Chlorhexidine gluconate 0.12% oral rinse prescribing information. U.S. National Library of Medicine.
2. Dentsply Sirona. (n.d.). NUPRO chlorhexidine gluconate oral rinse product information. Dentsply Sirona.
3. Addy, M., & Moran, J. (1987). Clinical indications for the use of chemical adjuncts to plaque control: Chlorhexidine formulations. Periodontology 2000, 15, 52-54.
4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA.
5. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. FDA.
6. U.S. Food and Drug Administration. (n.d.). ANDA product-specific guidances. FDA.
7. Dentsply Sirona. (n.d.). Annual report and investor disclosures. Dentsply Sirona.